Robinson Chandler
Chief Executive Officer
Robinson Chandler has filed 8 SEC Form 4 filings (18 transaction rows) across 1 company, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: Oct 20, 2026.
On the most recent filing, Robinson Chandler is listed as Chief Executive Officer at Monopar Therapeutics. Inside the rolling window, Robinson Chandler reported no open-market purchases and 1 open-market sale totaling $2.6M in MNPR.
Companies traded
Other insiders at MNPR
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.6M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Robinson Chandler made?
Robinson Chandler has filed 8 SEC Form 4 filings (18 transaction rows) across 1 company since 2025.
Which companies does Robinson Chandler trade?
Robinson Chandler has filed SEC Form 4 disclosures for 1 company, including MNPR.
When was Robinson Chandler's most recent SEC Form 4 filing?
Robinson Chandler's most recent SEC Form 4 filing on Tracefour is dated Oct 20, 2026.
What is Robinson Chandler's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Robinson Chandler is listed as Chief Executive Officer.
What is Robinson Chandler's total buy and sell value in the current window?
Inside the rolling retention window, Robinson Chandler bought $0 and sold $2.6M based on SEC Form 4 filings.
What was Robinson Chandler's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 29,056 MNPR shares on 2026-09-24, worth $2.6M, per SEC Form 4 filings.